# Compare peptides side by side

Source: https://aminodesk.com/compare
Publisher: Amino Desk
Updated: 2026-11-17

Pick two to four compounds and see them side by side: evidence grade, legal status, what each is sold for and a one-line summary.

Loading the compound list.

## Common comparisons

- [Semaglutide, tirzepatide and retatrutide](https://aminodesk.com/compare?c=semaglutide,tirzepatide,retatrutide)
- [BPC-157, TB-500 and GHK-Cu](https://aminodesk.com/compare?c=bpc-157,tb-500,ghk-cu)
- [Sermorelin, ipamorelin, CJC-1295 and tesamorelin](https://aminodesk.com/compare?c=sermorelin,ipamorelin,cjc-1295,tesamorelin)
- [Semax and Selank](https://aminodesk.com/compare?c=semax,selank)
- [NAD+, MOTS-c and Epitalon](https://aminodesk.com/compare?c=nad,mots-c,epitalon)

## How to read it

- **The grade is about evidence.** It describes how strong the human research is for a compound's best-studied use. It is not a verdict on safety or legality.
- **"Sold for" is how a compound is marketed,** not what it has been shown to do. The one-line summary says what was actually tested.
- **This table shows the short facts only.** Each compound's full page has the trial results, dosing sources and safety information. For two pairs we have written a deeper comparison: [semaglutide vs tirzepatide](https://aminodesk.com/compare/semaglutide-vs-tirzepatide) and [BPC-157 vs TB-500](https://aminodesk.com/compare/bpc-157-vs-tb-500).

Nothing you select is saved or sent anywhere. General information, not medical advice.

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
